MoonLake Immunotherapeutics (MLTX) Announces Proposed Underwritten Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/4/2026
- Dow hits record high; Broadcom-led chip selloff weighs on Nasdaq
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- HSBC stays aggressive on stocks, asks what could turn it bearish
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Crypto stocks sink as Bitcoin hits a 4-month low
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
- After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
- After-Hours Stock Movers: PANW, CRWD, ZS, GTLB, ULTA
- After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
- After-Hours Stock Movers: DELL, MDB, AEO, NTAP, GAP, S, ADSK
- After-Hours Stock Movers: CRM, MRVL, SNOW, HPQ, DDOG, MDB, P, SNPS, BRZE, NCNO
MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering
June 26, 2023 4:01 PM EDTMoonLake Immunotherapeutics Announces Proposed Underwritten
Public Offering
ZUG, Switzerland, June 26, 2023 MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has commenced an underwritten public offering of $250 million of its Class A ordinary shares and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase Class A ordinary shares. In addition, MoonLake is expected to grant the underwriters... More
